ArticleClinical pharmacology and therapeutics2026
Advancing Pharmacometrics in Africa: Insights and Perspectives From the 2025 Pharmacometrics Africa Conference.
Article in Clinical pharmacology and therapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Digital health in clinical pharmacy practice: transforming precision medicine and pharmacometrics in Africa.Frontiers in pharmacology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pharmacometrics (PMX) in Africa has transitioned from foundational capacity-building to job creation, scientific leadership, regulatory influence, and health innovation. To accelerate this progress, the 2025 Pharmacometrics Africa Conference (PMXAC-2025) convened key stakeholders to consolidate the continental PMX community, review progress in local capacity, and define priorities for African-led quantitative pharmacology and regulation. Held as a hybrid event in Kampala, Uganda, PMXAC-2025 featured plenary sessions, technical workshops, and poster presentations. A pre-conference nlmixr2 workshop strengthened open-source modeling expertise, while eight presentations and 32 posters facilitated discussions on capacity development, regulatory integration, and methodological innovation. The conference brought together 108 delegates, including 40 online participants from 14 countries (six African), reflecting strong global engagement. Regulatory representation (4.6%) demonstrated growing interdisciplinary collaboration. Sessions highlighted PMX as central to evidence-based healthcare, with applications in regulatory harmonization, patient-centered dosing, and equitable access. Presentations on model-based bioequivalence (MBBE), physiologically based pharmacokinetic (PBPK) modeling for safely extrapolating drug exposure in complex, understudied populations such as pregnant women and children, and model-based meta-analysis (MBMA) illustrated data-driven solutions for resource-limited settings. Emphasis on open-source tools reinforced technical equity, while career discussions promoted mentorship and cross-border collaboration. A closing panel outlined eight priorities for sustained progress, including funding, leadership, and integrated multi-sector partnerships. PMXAC-2025 signaled Africa's transition toward PMX self-reliance and innovation, uniting continental and diaspora experts, advancing open science, and setting a roadmap for sustainable, model-informed drug development across the continent. To sustain this momentum, establishing PMXAC-2025 as a regular annual event was strongly recommended.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.